Pieris Pharmaceuticals, Inc. (PIRS)

NASDAQ: PIRS · IEX Real-Time Price · USD
1.69
-0.02 (-1.17%)
Aug 16, 2022 11:17 AM EDT - Market open
-1.17%
Market Cap 125.75M
Revenue (ttm) 27.19M
Net Income (ttm) -41.51M
Shares Out 74.41M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 71,596
Open 1.70
Previous Close 1.71
Day's Range 1.69 - 1.80
52-Week Range 1.51 - 6.15
Beta 1.01
Analysts Buy
Price Target 8.16 (+382.8%)
Earnings Date Aug 4, 2022

About PIRS

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammato... [Read more...]

Industry Biotechnology
CEO Stephen Yoder
Employees 124
Stock Exchange NASDAQ
Ticker Symbol PIRS
Full Company Profile

Financial Performance

In 2021, PIRS's revenue was $31.42 million, an increase of 7.14% compared to the previous year's $29.32 million. Losses were -$45.74 million, 22.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for PIRS stock is "Buy." The 12-month stock price forecast is 8.16, which is an increase of 382.84% from the latest price.

Price Target
$8.16
(382.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -27.27% and 64.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT Adjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23 ...

Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog...

Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology ...

Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Pieris Pharmaceuticals (PIRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts ...

Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology ...

After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)

The heavy selling pressure might have exhausted for Pieris Pharmaceuticals (PIRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree...

Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 41.67% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnolog...

Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022

BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology p...

3 Risky Stocks With Huge Potential Upside

Why risk-tolerant investors want to own Shopify, Silvergate Capital, and Pieris Pharmaceuticals.

Other symbols: SHOPSI

This Pharmaceutical Stock Could Be Your Lottery Ticket

Pieris Pharmaceuticals has several drugs in clinical trials, but it only takes one to make this stock a hit.

This Pharmaceutical Stock Could Bank Billions Soon

Pieris Pharmaceuticals has several collaborations in place with big pharma.

3 Biotechs That Will Crush the Bear

Our roundtable likes Doximity, Outset Medical, and Pieris Pharmaceuticals to outperform in 2022.

Other symbols: DOCSOM

Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.

Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.

Other symbols: HRTXLEGN

Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue Estimates

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.67% and 71.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST Initiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this year Dosed first patient ...

Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022

BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techn...

3 Biotechs That Will Soar Regardless of COVID-19

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

Other symbols: SANATXG

2 Risky Growth Stocks That Could Make You Filthy Rich

These two biotech stocks are set to report key clinical data later this year.

Other symbols: LPTX

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cin...

BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technol...

Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phas...

BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technol...

Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Don't?

Investors need to pay close attention to for Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.

Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techn...

Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-...

BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary...